CSIMarket Company Name, Ticker, Competitors, else..
 
Aquestive Therapeutics Inc   (NASDAQ: AQST)
Other Ticker:  
 
 
Price: $3.0900 $-0.04 -1.278%
Day's High: $3.19 Week Perf: -0.32 %
Day's Low: $ 3.04 30 Day Perf: -15.34 %
Volume (M): 761 52 Wk High: $ 6.23
Volume (M$): $ 2,351 52 Wk Avg: $3.84
Open: $3.13 52 Wk Low: $2.24



 Market Capitalization (Millions $) 281
 Shares Outstanding (Millions) 91
 Employees 80
 Revenues (TTM) (Millions $) 59
 Net Income (TTM) (Millions $) -35
 Cash Flow (TTM) (Millions $) 53
 Capital Exp. (TTM) (Millions $) 0

Aquestive Therapeutics Inc
Aquestive Therapeutics Inc. is a pharmaceutical company that focuses on developing and commercializing innovative products to address unmet medical needs. The company specializes in oral drug delivery solutions, offering proprietary technology platforms that enable the development of orally administered therapeutics for a wide range of diseases and conditions. Aquestive Therapeutics aims to improve the treatment experience for patients by providing alternatives to injections or infusions. The company's portfolio includes products for central nervous system and neurology disorders, as well as treatments for rare diseases. Aquestive Therapeutics is dedicated to advancing drug delivery technology and transforming the way medications are administered.


   Company Address: 30 Technology Drive Warren 7059 NJ
   Company Phone Number: 941-1900   Stock Exchange / Ticker: NASDAQ AQST


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV      % 
ABT      % 
BMY      % 
JNJ      % 
MRK      % 
PFE      % 
• View Complete Report
   



Management Announcement

Headlining Innovation Amid Losses: Aquestive Therapeutics Charts 2025 Course with Focus on Pediatric Epilepsy Solutions

Published Mon, Jan 13 2025 12:01 PM UTC

As 2025 unfolds, a spotlight shines on Aquestive Therapeutics Inc. (NASDAQ: AQST), a Warren, N.J.-based pharmaceutical company currently navigating both turbulent fiscal waters and vital advancements in pediatric neurology. The firm recently shared a multi-faceted business update underscoring its commitment to innovative drug delivery platforms and focused objectives. Howev...
Product Service News

U.S. FDA Grants Orphan Drug Exclusivity to Aquestive Therapeutics for Libervant (Diazepam) Buccal Film in Young Pedia...

Published Thu, Dec 19 2024 1:00 PM UTC

Factual In a significant advancement for pediatric neurology, Aquestive Therapeutics has announced that the United States Food and Drug Administration (U.S. FDA) has granted Orphan Drug Exclusivity for its product, Libervant (diazepam) Buccal Film. This approval specifically pertains to the treatment of seizure clusters in children aged two to five years.Orphan Drug Exclusi...
Management Announcement

Aquestive Therapeutics Takes a Leap Forward with FDA Approval of Non-Injection Epinephrine Product: Anaphylaxis Treatment Revolutionized

Published Wed, Aug 14 2024 12:00 PM UTC



Aquestive Therapeutics, a pioneering pharmaceutical company known for its innovative science and delivery technologies, made...
Aquestive Therapeutics Inc

Aquestive Therapeutics Inc. Stock Performance Surges in 2024 despite Decline in Share Price

Aquestive Therapeutics Inc, a pharmaceutical company focused on innovative science and delivery technologies, has seen a significant improvement in its stock performance over the past year. As of the second quarter of 2024, the stock has improved by 79.59% compared to a year ago. However, during this same period, the share price has declined by -14.77%.
Currently trading on the NASDAQ, Aquestive Therapeutics Inc's stock is performing strongly, with a value that is 47.5% above its 52-week average. This suggests that investors have confidence in the company's future prospects.
Product Service News

Unlocking New Possibilities: Aquestive Therapeutics Bolsters Pediatric Epilepsy Care and Advances Anaphylaxis Treatment

Published Mon, Apr 29 2024 11:00 AM UTC

Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm (epinephrine) Sublingual FilmWARREN, N.J., April 29, 2024 - Aquestive Therapeutics, a leading pharmaceutical company focused on innovative science and delivery technologies, has made significant advancement...






Aquestive Therapeutics Inc's Segments
United States    77.74 % of total Revenue
Ex-United States    22.26 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com